The first domestic targeted il-36r monoclonal antibody was administered to the first subject in New Zealand
According to the official account of WeChat, Shanghai, China's Limited by Share Ltd has announced that the HB0034 project, the first recombinant IL-36R monoclonal antibody against human IL-36R, has been completed in New Zealand. The phase ia clinical study conducted in New Zealand aims to evaluate the safety, tolerance, immunogenicity and pharmacokinetics of hb0034 in healthy subjects. Huaaotai biology is a subsidiary of Huahai pharmaceutical, a listed company.
This text is a result of machine translation.
Related companies：
Briefing Oct 20, 2023 06:03 PM
· Technology
China’s OpenAI Challenger Zhipu AI Secures Over CNY 2.5 Billion to Step Further on Large-Scale Model
In-depth
Technology
ePropulsion: Pioneering Electric Marine Propulsion for a Sustainable Future
EqualOcean recently had an insightful conversation with Mr. Tao Shizheng, the visionary founder of ePropulsion (Chinese: 逸动科技), we embarked on a journey to understand the essence of the company's profound impact on the electric marine propulsion industry.
Jan 25, 2024 02:24 PM
Briefing Sep 18, 2023 07:40 PM
· Technology
4Paradigm Initiates IPO Today and Targets HKSE on September 28
Briefing Feb 23, 2023 10:59 AM
· Technology
Power Device Company Maplesemi Completes Series A+ Financing Round
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
Jan 05, 2023 07:33 PM
Nov 16, 2022 05:19 PM
Briefing Aug 26, 2021 06:31 PM
· Healthcare
Huahai pharmaceutical: the net profit in the first half of the year was 516 million yuan, a year-on-year decrease of 10.84%
See more
Read next
Insight
In-depth
Insight
In-depth